株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ぶどう膜炎 : パイプライン分析

Uveitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 219766
出版日 ページ情報 英文 194 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
ぶどう膜炎 : パイプライン分析 Uveitis - Pipeline Review, H2 2016
出版日: 2016年09月30日 ページ情報: 英文 194 Pages
概要

ぶどう膜炎とは、ぶどう膜(眼球の中間層(虹彩・毛様体・脈絡膜))の炎症・刺激作用のことを指します。片眼だけが発症することもあれば、両眼とも発症することもあります。発症の原因として、自己免疫障害(関節リウマチ、強直性脊椎症ほか)や感染症、毒素への被爆などが考えられます。主な症状として、視力低下、飛蚊症、眼球痛、充血、羞明などが挙げられます。疾病素質には、感染症への感染や自己免疫/炎症性疾患、目の外傷の経歴などが含まれています。主な治療薬にはステロイド系目薬や抗炎症剤、抗生物質、抗ウイルス薬などがあります。

当レポートでは、世界各国でのぶどう膜炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

ぶどう膜炎の概要

治療薬の開発

  • ぶどう膜炎向けパイプライン製品:概要
  • ぶどう膜炎向けパイプライン製品:比較分析

各企業で開発中のぶどう膜炎治療薬

大学/研究機関で研究中のぶどう膜炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

ぶどう膜炎治療薬:開発中の製品の一覧(企業別)

ぶどう膜炎治療薬:研究中の製品の一覧(大学/研究機関別)

ぶどう膜炎治療薬の開発に従事している企業

  • 2-BBB Medicines BV
  • AbbVie Inc.
  • Aciont Inc.
  • Aldeyra Therapeutics, Inc.
  • Apitope International NV
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd.
  • Clearside BioMedical, Inc.
  • Effimune SAS
  • Endocyte, Inc.
  • Enzo Biochem, Inc.
  • EyeGate Pharmaceuticals, Inc.
  • HanAll Biopharma Co., Ltd.
  • Icon Bioscience, Inc.
  • IMMD Inc.
  • Innomedica Ltd.
  • Johnson & Johnson
  • Kineta, Inc.
  • Neuroptis Biotech
  • Novartis AG
  • Ocata Therapeutics, Inc.
  • OncoNOx ApS
  • Palatin Technologies, Inc.
  • Panoptes Pharma Ges.m.b.H.
  • Pfizer Inc.
  • pSivida Corp.
  • Regeneron Pharmaceuticals, Inc.
  • 参天製薬
  • SynDevRx, Inc.
  • ThromboGenics NV
  • TxCell SA
  • Virogenomics, Inc.
  • XOMA Corporation

ぶどう膜炎:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 2B3-201
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • アバタセプト
  • アダリムマブ
  • ATXUV-1
  • ATXUV-2
  • B27-PD
  • セレコキシブ
  • Col-Treg
  • シクロスポリン SR
  • Cytectin
  • dalazatide
  • 酢酸デキサメタゾン
  • 酢酸デキサメタゾン
  • デキサメタゾンリン酸ナトリウム
  • 慢性ぶどう膜炎治療薬
  • 免疫学・眼科学・感染症・代謝障害・呼吸器系疾患向けアルドース還元酵素阻害剤
  • EC-1496
  • EC-1669
  • フルオシノロンアセトニド SR
  • FR-104
  • ゲボキズマ
  • HL-036
  • IMD-0354
  • INV-17
  • LFG-316
  • LME-636
  • ロダミン
  • methotrexate
  • NOP-3
  • NS-2
  • ブドウ膜炎向けIL-10活性化オリゴヌクレオチド
  • OX-1001
  • PA-2612
  • ブドウ膜炎向けTCR調整用ペプチド
  • piclidenoson
  • PL-8177
  • plastoquinone decyl triphenylphosphonium bromide
  • PP-001
  • PPL-003
  • ブドウ膜炎向け遺伝子組み換え型酵素
  • サリルマブ
  • シロリムス
  • ブドウ膜炎向け 5-lipoxygenase阻害小分子
  • 自己免疫疾患向け幹細胞療法
  • TG-931
  • TOP-1288
  • トリアムシノロンアセトニド
  • トリアムシノロンアセトニド

ぶどう膜炎治療薬:パイプライン製品の最新動向

ぶどう膜炎治療薬:開発が休止状態の製品

ぶどう膜炎治療薬:開発が中止された製品

ぶどう膜炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8544IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H2 2016, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 8, 2, 1, 26 and 6 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Uveitis.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Uveitis Overview
  • Therapeutics Development
    • Pipeline Products for Uveitis - Overview
    • Pipeline Products for Uveitis - Comparative Analysis
  • Uveitis - Therapeutics under Development by Companies
  • Uveitis - Therapeutics under Investigation by Universities/Institutes
  • Uveitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Uveitis - Products under Development by Companies
  • Uveitis - Products under Investigation by Universities/Institutes
  • Uveitis - Companies Involved in Therapeutics Development
    • 2-BBB Medicines BV
    • AbbVie Inc
    • Aciont Inc.
    • Aldeyra Therapeutics Inc
    • Apitope International NV
    • Astellas Pharma Inc.
    • Bionomics Limited
    • Bristol-Myers Squibb Company
    • Can-Fite BioPharma Ltd.
    • Clearside BioMedical, Inc.
    • Endocyte, Inc.
    • Enzo Biochem, Inc.
    • EyeGate Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd.
    • HanAll Biopharma Co., Ltd.
    • Icon Bioscience, Inc.
    • KPI Therapeutics, Inc.
    • Midatech Pharma Plc
    • Mitotech S.A.
    • Neuroptis Biotech
    • Novartis AG
    • Oculis ehf
    • OncoNOx ApS
    • OSE Immunotherapeutics
    • Palatin Technologies, Inc.
    • Panoptes Pharma Ges.m.b.H.
    • Pfizer Inc.
    • Precision Ocular Ltd
    • pSivida Corp.
    • Regeneron Pharmaceuticals Inc
    • Santen Pharmaceutical Co., Ltd.
    • SynDevRx, Inc.
    • TopiVert Ltd
    • TxCell SA
  • Uveitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 2-B3201 - Drug Profile
    • abatacept - Drug Profile
    • adalimumab - Drug Profile
    • ANV-103 - Drug Profile
    • ATXUV-1 - Drug Profile
    • ATXUV-2 - Drug Profile
    • B27-PD - Drug Profile
    • BNC-164 - Drug Profile
    • celecoxib - Drug Profile
    • Col-Treg - Drug Profile
    • CVX-001 - Drug Profile
    • cyclosporine SR - Drug Profile
    • dalazatide - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone sodium phosphate - Drug Profile
    • Drug for Chronic Uveitis - Drug Profile
    • Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile
    • EBI-031 - Drug Profile
    • EC-1669 - Drug Profile
    • EYS-606 - Drug Profile
    • fluocinolone acetonide SR - Drug Profile
    • FR-104 - Drug Profile
    • Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis - Drug Profile
    • HL-036 - Drug Profile
    • HO-10 - Drug Profile
    • INV-17 - Drug Profile
    • IVMED-10 - Drug Profile
    • IVMED-20 - Drug Profile
    • KPI-190 - Drug Profile
    • LME-636 - Drug Profile
    • lodamin - Drug Profile
    • methotrexate - Drug Profile
    • NOP-3 - Drug Profile
    • NS-2 - Drug Profile
    • OX-1001 - Drug Profile
    • piclidenoson - Drug Profile
    • PL-8177 - Drug Profile
    • plastoquinone decyl triphenylphosphonium bromide - Drug Profile
    • PP-001 - Drug Profile
    • PPL-003 - Drug Profile
    • Recombinant Enzymes for Uveitis - Drug Profile
    • sarilumab - Drug Profile
    • sirolimus - Drug Profile
    • Small Molecules to Inhibit 5-Lipoxygenase for Uveitis - Drug Profile
    • Stem Cell Therapy for Autoimmune Diseases - Drug Profile
    • tesidolumab - Drug Profile
    • TOP-1288 - Drug Profile
    • triamcinolone acetonide - Drug Profile
  • Uveitis - Dormant Projects
  • Uveitis - Discontinued Products
  • Uveitis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Uveitis, H2 2016
  • Number of Products under Development for Uveitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Uveitis - Pipeline by 2-BBB Medicines BV, H2 2016
  • Uveitis - Pipeline by AbbVie Inc, H2 2016
  • Uveitis - Pipeline by Aciont Inc., H2 2016
  • Uveitis - Pipeline by Aldeyra Therapeutics Inc, H2 2016
  • Uveitis - Pipeline by Apitope International NV, H2 2016
  • Uveitis - Pipeline by Astellas Pharma Inc., H2 2016
  • Uveitis - Pipeline by Bionomics Limited, H2 2016
  • Uveitis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Uveitis - Pipeline by Can-Fite BioPharma Ltd., H2 2016
  • Uveitis - Pipeline by Clearside BioMedical, Inc., H2 2016
  • Uveitis - Pipeline by Endocyte, Inc., H2 2016
  • Uveitis - Pipeline by Enzo Biochem, Inc., H2 2016
  • Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016
  • Uveitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Uveitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Uveitis - Pipeline by Icon Bioscience, Inc., H2 2016
  • Uveitis - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Uveitis - Pipeline by Midatech Pharma Plc, H2 2016
  • Uveitis - Pipeline by Mitotech S.A., H2 2016
  • Uveitis - Pipeline by Neuroptis Biotech, H2 2016
  • Uveitis - Pipeline by Novartis AG, H2 2016
  • Uveitis - Pipeline by Oculis ehf, H2 2016
  • Uveitis - Pipeline by OncoNOx ApS, H2 2016
  • Uveitis - Pipeline by OSE Immunotherapeutics, H2 2016
  • Uveitis - Pipeline by Palatin Technologies, Inc., H2 2016
  • Uveitis - Pipeline by Panoptes Pharma Ges.m.b.H., H2 2016
  • Uveitis - Pipeline by Pfizer Inc., H2 2016
  • Uveitis - Pipeline by Precision Ocular Ltd, H2 2016
  • Uveitis - Pipeline by pSivida Corp., H2 2016
  • Uveitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
  • Uveitis - Pipeline by SynDevRx, Inc., H2 2016
  • Uveitis - Pipeline by TopiVert Ltd, H2 2016
  • Uveitis - Pipeline by TxCell SA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Uveitis - Dormant Projects, H2 2016
  • Uveitis - Dormant Projects (Contd..1), H2 2016
  • Uveitis - Dormant Projects (Contd..2), H2 2016
  • Uveitis - Dormant Projects (Contd..3), H2 2016
  • Uveitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Uveitis, H2 2016
  • Number of Products under Development for Uveitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top